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Case report
  In July 2010, a 40-year-old woman presented to her 
primary care physician with a two-week history of  a tender 
palpable lump in her left breast. The patient denied ery-
thema, fever, skin changes, or nipple discharge. She re-
ported no personal or family history of  breast cancer. Her 
medical history was significant for recurring retroareolar 
granulomatous mastitis in the contralateral (right) breast 
treated previously with antibiotics, incision and drainage, 
and ultimately lumpectomy in June 2007. 
On physical exam, a 10-mm mass was palpated in the 
left breast at the 10 o’clock position, medial to the areola. A 
screening mammogram performed four months earlier 
demonstrated scattered fibroglandular densities bilaterally 
with mild stable architectural distortion in the right ret-
roareolar region at the site of  prior benign lumpectomy, 
and bilateral benign secretory calcifications (Figs. 1a, b). No 
suspicious masses or microcalcifications were noted in ei-
ther breast. 
To evaluate the palpable mass, the patient was referred 
for diagnostic mammography of  the left breast. Cranio-
caudal and mediolateral oblique views, with and without 
spot compression of  the subareolar region, were acquired 
and demonstrated a 10.0-mm, partially circumscribed mass 
in the anterior third of  the left breast at the 9 o’clock posi-
tion. Ultrasonography showed a solid mass with ill-defined 
borders. The lesion was given a Breast Imaging-Reporting 
and Data System score of  4. She was referred for 
ultrasound-guided core biopsy of  the left breast mass. Be-
fore biopsy, the patient consented to participation in an 
ongoing Institutional Review Board-approved clinical trial 
of  contrast-enhanced dedicated breast computed tomogra-
phy (CE-bCT) and underwent a CE-bCT study. Pathology 
from the left breast core biopsy revealed granulomatous 
inflammation, and it was recommended that the patient 
follow up in 1 year with routine screening mammography. 
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Dedicated breast computed tomography (bCT) generates high-resolution, three-dimensional images of  
the pendent uncompressed breast. Intravenous iodinated contrast during bCT provides additional physi-
ologic information. In this case, a 10.0-mm invasive ductal carcinoma was visualized using contrast-
enhanced bCT one year before mammographic detection. Mammography four months before bCT was 
negative. The bCT contrast enhancement pattern closely matched the dynamic contrast-enhanced MRI 
obtained after diagnosis. Lesion enhancement at contrast-enhanced breast CT matched previously pub-
lished enhancement values of  breast cancer. Contrast-enhanced dedicated bCT provided high-resolution 
tomographic images and physiologic contrast enhancement data that facilitated the detection of  an early 
breast cancer.
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CE-bCT is a fully tomographic, cone-beam-x-ray-based 
imaging modality that generates three-dimensional images 
of  the pendent uncompressed breast (1). The X-ray tube 
potential is set to 80 kVp, and the tube current is selected 
according to the patient’s breast size and mammographic 
density to deliver a mean glandular dose equivalent to that 
of  a two-view screening mammogram. A CE-bCT proce-
dure consists of  four scans, imaging the left and right 
breasts before and after the injection of  100 ml of  iodi-
nated contrast (Visipaque 320; GE Healthcare, Waukesha, 
WI) at a rate of  4 ml/s (2). 
The patient’s bCT was acquired with a 75-second delay 
from the start of  contrast injection before imaging the left 
breast and a 268-second contrast delay time when imaging 
the right breast, since the breasts are imaged individually. 
An 11.0-mm mass was identified at the 9 o’clock position of 
the left breast, corresponding to the biopsy-proven granu-
lomatous inflammation. In the right breast, an 8.1-mm 
central, oval mass and a 14.5 x 8.0 x 6.7-mm ill-defined 
enhancing mass at the 9 o’clock position were identified 
(Fig. 2). The 9 o’clock mass was also associated with areas 
of  nonmass-like enhancement. Using a previously de-
scribed technique (2), the left breast mass was quantified to 
enhance by 48.9 Hounsfield units (HU), and the right 
breast lesions were quantified to enhance by 27.8 HU (cen-
tral lesion) and 58.4 HU (9 o’clock). Since bCT is an ex-
perimental imaging modality undergoing clinical trials, the 
right breast findings could not be used to guide patient 
care.
One year later (July 2011), the patient returned for a 
regular screening mammogram that identified a 10.0-mm 
mass at the 12 o’clock position in the right breast. At ultra-
sonography, a second ill-defined, hypoechoic, heterogene-
ous mass was identified at the 10 o’clock position in the 
right breast, measuring 12.0 mm x 1.0 mm x 12.0 mm. 
The secondary lesion was retrospectively visualized on the 
screening mammogram as well (Figs. 1c, d). Both masses 
underwent core biopsy by ultrasound guidance. The 12 
o’clock mass was diagnosed as a benign fibroadenoma. The 
10 o’clock mass was diagnosed at core biopsy as a Stage I 
invasive ductal carcinoma with associated ductal carcinoma 
in situ (Fig. 3). The tumor was estrogen- and progesterone-
receptor positive and Her2/neu amplification 
negative. 
     A right breast lumpectomy was planned, 
and a dynamic contrast-enhanced MRI (DCE-
MRI) was obtained to evaluate the extent of  
disease. On DCE-MRI, the invasive ductal 
carcinoma (10 o’clock) was seen as an ill-
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Fig. 2. Pre- (a) and postcontrast (b) co-
ronal, sagittal, and axial bCT images of the 
right breast from July 2010 demonstrate an 
irregular enhancing mass at the 9 o’clock 
position (invasive ductal carcinoma) (arrow) 
and an oval enhancing mass at the 12 
o’clock position (fibroadenoma) (arrow-
head). 
Fig. 1. Right craniocaudal (a) and mediolateral oblique (b) 
screening mammograms from April 2010 show no evidence 
of disease. Right craniocaudal (c) and mediolateral oblique 
(d) screening mammograms from July 2011 demonstrate 
two suspicious lesions at the 10 o’clock (arrow) and 12 
o’clock (arrowhead) positions, diagnosed as invasive ductal 
carcinoma and a fibroadenoma, respectively. 
defined enhancing mass with rapid initial enhancement and 
washout characteristics. An associated area of  heterogene-
ous nonmass enhancement was also seen. The enhance-
ment pattern observed in the right breast at DCE-MRI, 
performed after biopsy, matched closely that observed at 
CE-bCT performed approximately one year earlier, before 
biopsy (Fig. 4). Over the course of  one year, the lesion size 
changed from 14.5 x 8.0 x 6.7 mm (as measured at CE-
bCT) to 12.0 mm (as measured at DCE-MRI). The screen-
ing mammogram acquired four months prior to the CE-
bCT procedure showed no signs of  disease. While four 
months may account for several doubling times, it is un-
likely that such a lesion would develop in this amount of  
time. 
Discussion
 This paper presents, to our knowledge, the first reported 
case of  breast cancer detection and diagnosis using CE-
bCT prior to detection using standard-of-care imaging 
techniques. The size of  the lesion at CE-bCT was smaller 
than the size at mammography one year later (14.5 x 8.0 x 
6.7 mm versus 12 mm), emphasizing the potential for early 
cancer detection with CE-bCT.
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Fig. 3. Light microscopy at 4x magnification with hematoxylin and eosin stain demonstrating inva-
sive ductal carcinoma. 
Fig. 4. Axial, fat-saturated T1 early post-contrast MRI (July 2011) (a) and contrast-enhanced bCT 
(July 2010) (b) images of the right breast demonstrate similar enhancement pattern, with an en-
hancing invasive ductal carcinoma at the 10 o’clock position (arrow) and a minimally enhancing 
fibroadenoma at the 12 o’clock position (arrowhead). The first DCE-MRI time point is shown (90 s) 
and was performed using 0.1 mmol/kg gadolinium-based contrast medium injection (Omniscan; 
GE Healthcare, Waukesha, WI).
Previously, we have shown CE-bCT to be superior in 
visualizing malignant masses when compared to mammog-
raphy (2). Visualization of  malignant lesions manifested by 
microcalcifications was initially demonstrated to be superior 
at mammography than at bCT (1), but with injected iodine 
contrast, visualization with CE-bCT and mammography 
may be equivalent (2). The case presented here further sug-
gests that the high-contrast tomographic images of  CE-
bCT provide a temporal benefit for earlier visualization of  
malignancy.
We have also previously demonstrated that malignant 
and benign lesions enhance at CE-bCT by an average of  
55.9 and 17.6 HU (2), respectively. In this patient, the inva-
sive ductal carcinoma enhanced by a similar amount as the 
published average for malignant lesions, but the fibroade-
noma enhanced more than the average benign lesion. This 
may be due to the long contrast delay time (268 s) and the 
persistent enhancement kinetics observed in the fibroade-
noma. The benign lesion in the left breast also demon-
strated contrast-enhancement (48.9 HU), possibly due to 
the active inflammatory process. Areas of  inflammation or 
active wound healing may enhance and represent false 
positive findings. The use of  a more optimal delay time 
when imaging the right breast may have increased the dif-
ferential enhancement of  the malignant lesion and im-
proved specificity. Studies are currently under way to iden-
tify the optimal delay time for CE-bCT imaging with possi-
ble simultaneous imaging of  both breasts.
In this patient, CE-bCT detected an invasive ductal car-
cinoma one year before any symptoms or mammographic 
signs. The lesion morphology and enhancement pattern on 
CE-bCT closely matched the MRI findings. Quantification 
of  lesion enhancement provided physiological data that 
aided differentiation of  benign and malignant lesions. 
While the sensitivity and specificity of  CE-bCT have yet to 
be established, this modality may serve as an alternative to 
DCE-MRI for breast cancer screening in high-risk popula-
tions and for staging malignancies. With better understand-
ing of  iodine contrast enhancement and further kinetic 
optimization, CE-bCT may serve a useful role in early 
breast cancer detection and diagnosis.
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